GRACEcast Radiation Oncology Video

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

23 Aug 2013

Contributed by Lukas

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive ...

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

23 Aug 2013

Contributed by Lukas

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive ...

ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (video)

23 Aug 2013

Contributed by Lukas

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers ...

ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)

23 Aug 2013

Contributed by Lukas

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers ...

ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)

16 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunit...

ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

16 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunit...

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)

16 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit o...

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)

16 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit o...

ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (video)

15 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the ...

ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)

15 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the ...

Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

15 Aug 2013

Contributed by Lukas

Dr. Rosalyn Juergens, McMaster University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will b...

Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"

15 Aug 2013

Contributed by Lukas

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular m...

Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (video)

14 Aug 2013

Contributed by Lukas

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with t...

Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (audio)

14 Aug 2013

Contributed by Lukas

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with t...

ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (video)

14 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to ch...

ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)

14 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to ch...

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (video)

13 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

13 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (video)

11 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unres...

ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)

11 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unres...

ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (video)

07 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduct...

ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)

07 Aug 2013

Contributed by Lukas

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduct...

Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

06 Aug 2013

Contributed by Lukas

Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especiall...

Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors

06 Aug 2013

Contributed by Lukas

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).

Dr. David Spigel on "Which molecular marker tests do you seek?"

29 Jul 2013

Contributed by Lukas

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.

HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (video)

22 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from r...

HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (audio)

22 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from r...

HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (video)

22 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant pro...

HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)

22 Jul 2013

Contributed by Lukas

GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and...

Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (video)

21 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potent...

Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (audio)

21 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potent...

Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (video)

18 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck c...

Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (audio)

18 Jul 2013

Contributed by Lukas

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck c...

Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

11 Jul 2013

Contributed by Lukas

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat...

Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

11 Jul 2013

Contributed by Lukas

Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular onc...

Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

11 Jul 2013

Contributed by Lukas

Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung ...

Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"

11 Jul 2013

Contributed by Lukas

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.

Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

11 Jul 2013

Contributed by Lukas

Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.

Is there a place for maintenance therapy in extensive stage NSCLC?

04 Jul 2013

Contributed by Lukas

Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC s...

How should we integrate new immunotherapies into treatment strategies for lung cancer?

04 Jul 2013

Contributed by Lukas

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatme...

How do we approach acquired resistance to targeted therapies in lung cancer?

04 Jul 2013

Contributed by Lukas

Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanc...

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

04 Jul 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

04 Jul 2013

Contributed by Lukas

Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung c...

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

04 Jul 2013

Contributed by Lukas

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results an...

Can we target KRAS effectively in advanced NSCLC?

02 Jul 2013

Contributed by Lukas

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of N...

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

02 Jul 2013

Contributed by Lukas

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repe...

Could BRAF be a new target in NSCLC?

27 Jun 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients w...

Are molecular markers just for NSCLC?

21 Jun 2013

Contributed by Lukas

Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lu...

Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

21 Jun 2013

Contributed by Lukas

Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncol...

Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

21 Jun 2013

Contributed by Lukas

Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.

Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?

19 Jun 2013

Contributed by Lukas

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120...

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

19 Jun 2013

Contributed by Lukas

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive a...

Can we harness our immune system to fight NSCLC?

19 Jun 2013

Contributed by Lukas

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based the...

Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

19 Jun 2013

Contributed by Lukas

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combi...

Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

15 Jun 2013

Contributed by Lukas

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google...

Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

15 Jun 2013

Contributed by Lukas

Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.

Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

15 Jun 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG ...

Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

13 Jun 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compar...

Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

12 Jun 2013

Contributed by Lukas

Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to...

Can we predict which patients will benefit from Tarceva based on a blood test?

12 Jun 2013

Contributed by Lukas

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristra...

Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?

11 Jun 2013

Contributed by Lukas

Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.

Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

10 Jun 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select ...

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (video)

09 Jun 2013

Contributed by Lukas

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extens...

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)

09 Jun 2013

Contributed by Lukas

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extens...

Is it possible to test for biomarkers in lung cancer on a national scale?

07 Jun 2013

Contributed by Lukas

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in...

Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

04 Jun 2013

Contributed by Lukas

Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies wi...

Dr. Geoffrey Oxnard: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

04 Jun 2013

Contributed by Lukas

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with adv...

Dr. Rosalyn Juergens on "My Approach to Maintenance Therapy for Advanced NSCLC"

04 Jun 2013

Contributed by Lukas

Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for ...

Dr. Sarah Goldberg on "Which patients do you send molecular marker testing for?"

30 May 2013

Contributed by Lukas

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

Dr. Ravi Salgia: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

30 May 2013

Contributed by Lukas

Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the int...

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (video)

30 May 2013

Contributed by Lukas

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small...

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)

30 May 2013

Contributed by Lukas

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small...

Dr. David Spigel: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

28 May 2013

Contributed by Lukas

Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.

Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

28 May 2013

Contributed by Lukas

Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies wi...

Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?

24 May 2013

Contributed by Lukas

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the main types of kidney cancer and discusses the d...

Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

24 May 2013

Contributed by Lukas

Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a r...

Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

21 May 2013

Contributed by Lukas

Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the b...

Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

21 May 2013

Contributed by Lukas

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients wi...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (video)

20 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)

20 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung...

GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, Canada

17 May 2013

Contributed by Lukas

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy f...

Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

17 May 2013

Contributed by Lukas

Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care syst...

Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"

17 May 2013

Contributed by Lukas

Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.

Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"

17 May 2013

Contributed by Lukas

Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy ...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)

17 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-s...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

17 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-s...

Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?

15 May 2013

Contributed by Lukas

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line...

Dr. Larry Einhorn: Are You Optimistic That a Supercomputer Such as Watson Will Be Able To Improve Cancer Care?

15 May 2013

Contributed by Lukas

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on whether a supercomputer such as Wa...

Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

13 May 2013

Contributed by Lukas

Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will beco...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (video)

13 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early sta...

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)

13 May 2013

Contributed by Lukas

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early sta...

Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

11 May 2013

Contributed by Lukas

Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would...

Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

11 May 2013

Contributed by Lukas

Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially i...

Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

10 May 2013

Contributed by Lukas

Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lu...

Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

10 May 2013

Contributed by Lukas

Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver muta...

Dr. Greg Riely on "My Approach to Maintenance Therapy for Advanced NSCLC"

07 May 2013

Contributed by Lukas

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy ...

Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

07 May 2013

Contributed by Lukas

Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for pati...

Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (video)

04 May 2013

Contributed by Lukas

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for sy...

Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (audio)

04 May 2013

Contributed by Lukas

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for sy...

Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?

02 May 2013

Contributed by Lukas

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the role of surgery in the treatment of metastatic ...